Search

Your search keyword '"Drugs -- Economic aspects"' showing total 81 results
Start Over Descriptor "Drugs -- Economic aspects" Topic health care industry
81 results on '"Drugs -- Economic aspects"'

1. Skyrocketing drug costs hits Blue Cross bottom line

Subjects
Blue Cross and Blue Shield of Michigan -- Officials and employees, Health insurance industry -- Officials and employees, Health care industry -- Officials and employees, Drugs -- Economic aspects, Health care industry, Business, Business, regional
Abstract

Byline: Dustin Walsh In 2023, more Michiganders used health care services and used novel drugs to relieve ailments. That exacted a cost on Blue Cross Blue Shield of Michigan's bottom [...]

Published
2024

2. ScriptSave and Rx Outreach use first-of-its-kind tool to reduce medication costs for America's most vulnerable people

Subjects
Patient compliance -- Economic aspects, Drugstores -- Economic aspects, Health care industry -- Economic aspects, Drugs -- Economic aspects, Pharmacy -- Economic aspects, Health care industry, Business, News, opinion and commentary
Abstract

Dedicated wireless device enables clinics to identify the pharmacy with the lowest-cost drug for each patient TUCSON, Ariz. and ST. LOUIS, May 29, 2024 /PRNewswire/ -- ScriptSave, a trusted provider [...]

Published
2024

3. Digbi Health Selected by State Public Health Insurance Trust to Manage Obesity Treatment Costs Amid Escalating GLP-1 Drug Expenses

Subjects
Obesity -- Economic aspects, Chronic diseases -- Economic aspects, Drugs -- Economic aspects, Public health -- Economic aspects, Type 2 diabetes -- Economic aspects, Company business management, Health care industry
Abstract

2024 AUG 27 (NewsRx) -- By a News Reporter-Staff News Editor at Managed Care Business Week -- Digbi Health, a leader in Precision Biology for obesity and chronic disease management, [...]

Published
2024

4. A Look at Biden's Proposed Budget

Author

Bushak, Lecia

Subjects
Health care reform -- Economic aspects, Medical care, Cost of -- Economic aspects, Mental health -- Economic aspects, Drugs -- Economic aspects, Behavioral health care -- Economic aspects, Budget -- Economic aspects, Company financing, Business, Health care industry
Abstract

The administration's 2024 budget includes provisions on lowering drug prices, extending Medicare solvency and investing in mental health * President Joe Biden unveiled his 2024 budget proposal this week, outlining [...]

Published
2023

5. United Kingdom : Unused medicines cost Northern Ireland health system 18m per year

Subjects
Medical care, Cost of -- Economic aspects, Health care industry -- Economic aspects, Drugs -- Economic aspects, Health care industry, Business, international
Abstract

It has been previously estimated that medicines wasted in Northern Ireland are valued at 18 million annually. This is further compounded by 650,000 cost to safely dispose of these unused [...]

Published
2023

6. Unused medicines cost Northern Ireland health system PS18m per year

Subjects
Medical care, Cost of -- Economic aspects, Health care industry -- Economic aspects, Drugs -- Economic aspects, Health care industry, Business, international
Abstract

London: The Welsh Government has issued the following news release: Every year in Northern Ireland, the public disposes of an estimated 165 tonnes of unused medicines through community pharmacies. Most [...]

Published
2023

7. US Health Insurers to Weather Rising Drug and Input Costs, Higher Utilization

Subjects
Medical care, Cost of -- Economic aspects, Financial analysis -- Economic aspects, Health insurance industry -- Economic aspects -- Securities, Health care industry -- Securities -- Economic aspects, Drugs -- Economic aspects, Health care industry, Company securities, General interest, News, opinion and commentary
Abstract

New York: Fitch Ratings has issued the following commentary: U.S. health insurers have adequate ratings headroom to withstand the mounting cost pressures driven by growing drug shortages, rising pharmaceutical and [...]

Published
2023

8. Kalderos' 2023 annual report highlights costs of systemic challenges in drug discount programs and their impact on drug manufacturers, covered entities, payers and patients

Subjects
Medicaid -- Economic aspects, Health care industry -- Economic aspects, Drugs -- Economic aspects, Pharmaceutical industry -- Economic aspects, Health care industry, General interest, News, opinion and commentary
Abstract

CHICAGO: Kalderos has issued the following news release: Data infrastructure and analytics company Kalderos, creator of the world's first Drug Discount Management platform, released its 2023 annual report today. The [...]

Published
2023

9. Kalderos' 2023 annual report highlights costs of systemic challenges in drug discount programs and their impact on drug manufacturers, covered entities, payers and patients

Subjects
Medicaid -- Economic aspects, Drugs -- Economic aspects, Pharmaceutical industry -- Economic aspects, Health care industry
Abstract

2023 JUN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Managed Care Business Week -- Data infrastructure and analytics company Kalderos, creator of the world's first Drug Discount [...]

Published
2023

10. Medicine Costs for Ukrainian Refugees in Poland Covered by New Direct Cash Aid Program

Subjects
Social service -- Economic aspects, Medical economics -- Economic aspects, Drugstores -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Pharmacy -- Economic aspects, Health care industry, Business, News, opinion and commentary
Abstract

With $10 Million Commitment, Direct Relief and Pelion S.A. Will Cover Costs of Medicines at Pharmacies Across Poland WARSAW, Poland, April 15, 2022 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=3506520-1&h=3173870716&u=https%3A%2F%2Fwww.directrelief.org%2Fnews%2F&a=Direct+Relief and https://c212.net/c/link/?t=0&l=en&o=3506520-1&h=68893850&u=https%3A%2F%2Fwww.pelion.eu%2Fen%2F&a=Pelion+S.A. today announced [...]

Published
2022

11. iPHEX to showcase Indian pharma as the most affordable, sustainable and high quality compliant drugs in the world

Subjects
Drugs -- Economic aspects, Health care industry -- International economic relations -- Economic aspects, Parks, Pharmaceutical industry, Pharmaceutical policy, Health care industry, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau The International Pharmaceuticals and Healthcare Exhibition (iPHEX), India's own international exhibition platform, will bring together the pharmaceutical and healthcare industry under one roof. According to the Pharmaceutical [...]

Published
2019

13. Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic

Author

Raper, James L., Willig, James H., Lin, Hui-Yi, Allison, Jeroan J., Broner, M. Bennet, Mugavero, Michael J., and Saag, Michael S.

Subjects
HIV (Viruses) -- Drug therapy, Medical care, Cost of -- Research, Drugs -- Prescribing, Drugs -- Laws, regulations and rules, Drugs -- Economic aspects, Clinics -- Management, Government regulation, Company business management, Health, Health care industry
Published
2010

14. Beyond abuse and exposure: framing the impact of prescription-medication sharing

Author

Goldsworthy, Richard C., Schwartz, Nancy C., and Mayhorn, Christopher B.

Subjects
Sharing -- Psychological aspects, Sharing -- Analysis, Drugs -- Prescribing, Drugs -- Economic aspects, Drugs -- Analysis, Government, Health care industry
Abstract

Objectives. We sought to document the frequency, circumstances, and consequences of prescription medication-sharing behaviors and to use a medication-sharing impact framework to organize the resulting data regarding medication-loaning and -borrowing practices. Methods. One-on-one interviews were conducted in 2006, and participants indicated (1) prescription medicine taken in the past year, (2) whether they had previously loaned or borrowed prescription medicine, (3) scenarios in which they would consider loaning or borrowing prescription medicine, and (4) the types of prescription medicines they had loaned or borrowed. Results. Of the 700 participants, 22.9% reported having loaned their medications to someone else and 26.9% reported having borrowed someone else's prescription. An even greater proportion of participants reported situations in which medication sharing was acceptable to them. Conclusions. Sharing prescription medication places individuals at risk for diverse consequences, and further research regarding medication loaning and borrowing behaviors and their associated consequences is merited.

Published
2008

15. Nigeria: Cross River State Signs Onto the Biggest Pharma Transformation Project in History of Health Sector - Safer and Affordable Medicines for All!

Subjects
Medical care, Cost of -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Health care industry, News, opinion and commentary
Abstract

Cross River State Government has risen to the occasion to ensure that it achieves Universal quality health care at all cost for the people. It is on this basis that [...]

Published
2021

16. Feds call on insurers to fully cover HIV prevention drug PrEP without cost-sharing

Author

King, Robert

Subjects
HIV (Viruses) -- Prevention, Insurance policies -- Economic aspects, Drugs -- Economic aspects, Sexually transmitted diseases -- Prevention, HIV infection -- Prevention, Health care industry
Abstract

Byline: Robert King The Biden administration issued guidance Monday directing most insurers to offer pre-exposure prophylaxis (PrEP) to beneficiaries at no cost. The guidance released Monday (https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-47.pdf) by the Department [...]

Published
2021

17. Data on Health and Medicine Discussed by Researchers at University of Pennsylvania (Cost-effectiveness Analysis of Branded Drugs With Market Demand and Insurance)

Subjects
Cost benefit analysis -- Economic aspects, Drugs -- Economic aspects, Health insurance -- Economic aspects, Cost benefit analysis, Health care industry, University of Pennsylvania
Abstract

2021 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at Health Insurance Week -- Data detailed on Health and Medicine have been presented. According to news reporting originating [...]

Published
2021

18. Prescription drug spending: the impact of age and chronic disease status

Author

Mueller, Curt, Schur, Claudia, and O'Connell, Joan

Subjects
Drugs -- Economic aspects, Aged -- Drug use, Chronic diseases -- Economic aspects, Government, Health care industry
Abstract

Objectives. The purpose of this study was to examine how pharmaceutical expenditures vary by age and the presence of chronic health problems. Methods. Data from the 1987 National Medical Expenditure Survey were used to obtain nationally representative estimates of outpatient prescription drug expenditures for the noninstitutionalized population and the fraction of total health expenditures used to purchase medications for age-chronic disease population subgroups. Results. Although the elderly make up 12% of the population, they account for 34% of total pharmaceutical expenditures. Pharmaceutical expenditures are 9% of total expenditures for children, 13% for nonelderly adults, and 23% for the elderly. Among nonelderly adults, approximately one third have at least one chronic condition and account for over two thirds of drug expenditures. Among the elderly, 36% have three or more chronic conditions and account for 57% of drug expenditures for this group; 41% of total drug expenditures are for cardiovascular or renal drugs. Conclusions. Significant pharmaceutical spending is for treatment of chronic conditions, which subjects insurance coverage to adverse selection and could affect the design of prescription drug benefit packages. Current enrollees in Medicare risk management plans who have drug benefits may face significantly higher out-of-pocket expenses for pharmaceuticals if capitation rates are cut as a means of controlling Medicare program expenditures. (Am J Public Health. 1997;87:1626-1629)

Published
1997

19. Prescription drug spending: contribution to health care spending and cost containment strategies

Author

Rivers, Patrick A., Hall, Nina German, and Frimpong, Jemima

Subjects
Drugs -- Economic aspects, Health care industry -- Economic aspects, Health care industry, Business
Abstract

Prescription drug costs have been the focus of much research in the health care economy, within managed care organizations, and hospital systems. Pharmacy costs are drivers of general health care [...]

Published
2006

20. 6 questions to ask your healthcare provider about out-of-pocket medication costs

Subjects
Health care costs -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Pharmaceutical industry, Medical economics, Health care industry, News, opinion and commentary, Sports and fitness
Abstract

- Even in the privacy of a doctor's office, many patients hesitate to discuss one subject -- money. While nearly one in four Americans over the age of 50 feels [...]

Published
2019

21. 6 questions to ask your healthcare provider about out-of-pocket medication costs

Subjects
Health care costs -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Pharmaceutical industry, Medical economics, Health care industry, News, opinion and commentary, Sports and fitness
Abstract

- Even in the privacy of a doctor's office, many patients hesitate to discuss one subject -- money. While nearly one in four Americans over the age of 50 feels [...]

Published
2019

22. CONGRESSMAN PAPPAS HOLDS ROUNDTABLE DISCUSSION WITH NEW HAMPSHIRE NURSES TO DISCUSS THE RISING COSTS OF PRESCRIPTION DRUGS

Subjects
Congressional representatives -- Economic aspects, Nurse practitioners -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Associations -- Economic aspects, Prescriptions (Drugs) -- Economic aspects, Nurses, Legislators, Nursing, Health care industry, News, opinion and commentary
Abstract

MANCHESTER, N.H. -- The following information was released by the office of New Hampshire Rep. Chris Pappas: Today Congressman Chris Pappas gathered the New Hampshire Nursing Association, the New Hampshire [...]

Published
2019

23. Making cost-effectiveness part of your product

Author

McDonald, Robert C.

Subjects
Medical economics -- Evaluation, Pharmaceutical industry -- Product development, Product development -- Methods, Cost (Economics) -- Evaluation, Drugs -- Economic aspects, Business, Health care industry
Abstract

This first-hand report reveals how one company developed and implemented a program for incorporating economic assessment into its way of doing business. PERHAPS NO PROMOTIONAL TERM HAS BEEN SO widely [...]

Published
1994

25. Personalized medicine brings big wins to managed care: higher quality, lower costs on the horizon

Author

Walker, Tracey

Subjects
Economic aspects, Health care industry, Precision medicine -- Economic aspects, Evidence-based medicine -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Managed care plans (Medical care) -- Economic aspects, Therapeutics -- Economic aspects, Patient compliance -- Economic aspects
Abstract

Personalized medicine can make patients healthier while lowering systemic costs. That's according to a recent report from the Personalized Medicine Coalition (PMC), 'The Personalized Medicine Report: Opportunity, Challenges, and the [...]

Published
2017

26. Physician practice helps patients tackle high drug costs: Massachusetts general physicians organization patients can receive assistance with high drug costs through financial assistance plans offered by the physician organization, by enrolling in insurance coverage, or through state aid

Author

Hintch, Betty

Subjects
Government aid -- Economic aspects, Physicians -- Economic aspects, Drugs -- Economic aspects, Medical practice -- Economic aspects, Insurance -- Economic aspects, Government funding, Company financing, Insurance industry, Health care industry
Abstract

The rise in high-deductible health plans requires patients to pay higher out-of-pocket costs for the care they receive in hospitals and physicians' offices, as well as budget for ongoing drug [...]

Published
2015

27. The Health 202: Trump's latest move to lower drug spending pits patients versus insurers

Subjects
United States. Centers for Medicare and Medicaid Services, Aetna Inc., Insurance industry -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Insurance companies -- Economic aspects, Prescriptions (Drugs) -- Economic aspects, Pharmaceutical industry -- Economic aspects, Health insurance industry -- Economic aspects, Medicare, Drugstores, Insurance industry, Health care industry, Business, Computers and office automation industries, Telecommunications industry
Abstract

Byline: Paige Winfield CunninghamTHE PROGNOSISPatient advocates and health insurers are pitted against each other in the Trump administration's latest move to lower drug costs. The two groups disagree sharply over [...]

Published
2018

28. Blue Shield of California and Gemini Health Deliver Efficiencies, Savings with Innovative Drug-Cost Transparency Service

Subjects
Medical records -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Alternative medicine -- Economic aspects, Medical economics -- Economic aspects, Pharmaceutical industry -- Economic aspects, Health care industry, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Blue Shield of California has issued the following news release: Healthcare providers in California can now use a new Drug-Cost Transparency Service to view patient-specific lower-cost alternative medicines [...]

Published
2018

29. Blue Shield of California and Gemini Health Deliver Efficiencies, Savings with Innovative Drug-Cost Transparency Service

Subjects
Medical records -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Alternative medicine -- Economic aspects, Medical economics -- Economic aspects, Pharmaceutical industry -- Economic aspects, Health care industry, Business, international
Abstract

April 25 -- Healthcare providers in California can now use a new Drug-Cost Transparency ServiceTM to view patient-specific lower-cost alternative medicines and compare prices while meeting with patients in their [...]

Published
2018

30. Blue Shield of California and Gemini Health Deliver Efficiencies, Savings with Innovative Drug-Cost Transparency Service[TM]

Subjects
Medical records -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Alternative medicine -- Economic aspects, Medical economics -- Economic aspects, Pharmaceutical industry -- Economic aspects, Health care industry, Business, Business, international
Abstract

Providers get patient-specific drug-cost comparisons for prescriptions using their electronic health record system SAN FRANCISCO -- Healthcare providers in California can now use a new Drug-Cost Transparency Service[TM] to view [...]

Published
2018

31. Health-care alliance calls for action to lower prescription-drug costs

Author

McGinley, Laurie

Subjects
Drugs -- Economic aspects, Health care industry -- International economic relations -- Economic aspects, Health care industry, General interest, News, opinion and commentary
Abstract

Byline: Laurie McGinley A broad coalition including health-care providers, insurers and seniors will propose major changes today designed to rein in prescription-drug costs, including a shorter exclusivity period for biotech [...]

Published
2016

32. IMS Study Pinpoints Ways to Improve Medicine Use and Cut Healthcare Spending

Subjects
Medical care, Cost of -- Economic aspects, Health care reform -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Health care industry, Arts and entertainment industries
Abstract

The IMS Institute for Healthcare Informatics has identified six levers that can be applied to improve medicine use worldwide and empower public and private stakeholders to realize nearly a half-trillion [...]

Published
2012

33. EXPANDING ACCESS TO AFFORDABLE PRESCRIPTION DRUGS

Subjects
United States. Centers for Medicare and Medicaid Services, Drugs -- Economic aspects, Health care industry -- Economic aspects, Health care reform -- Economic aspects, Prescriptions (Drugs) -- Economic aspects, Health care industry, News, opinion and commentary
Abstract

WASHINGTON -- The following information was released by the office of Virginia Rep. Rob Wittman: Friend- Like you, I believe Congress must work to improve the affordability of the nation's [...]

Published
2017

34. In the OECD other health care services will be ten times prescription medicine spending growth over next decade

Subjects
Health care costs -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Patient care -- Economic aspects, Long term care -- Economic aspects, Pharmaceutical industry -- Economic aspects, Pharmaceutical policy -- Economic aspects, Prescriptions (Drugs) -- Economic aspects, Health care industry, General interest, News, opinion and commentary
Abstract

Washington, DC: Pharmaceutical Research and Manufacturers of America has issued the following news release: Now more than ever, innovative therapies are transforming care and providing cures for patients fighting life-threatening [...]

Published
2017

35. Vibcare Pharma Pvt. Ltd. Produces Affordable Drugs

Subjects
Drugs -- Economic aspects, Health care industry -- Economic aspects, Health care industry, Business, News, opinion and commentary
Abstract

MUMBAI, India, March 7, 2017 /PRNewswire/ -- Vibcare Pharma Pvt. Ltd. seeks to lead the market in the development, manufacturing and marketing drugs at low costs to the market. Through [...]

Published
2017

36. In brief

Subjects
Mortality -- Australia, Mortality -- Risk factors, Type 1 diabetes -- Complications and side effects, Bacterial vaccines -- Dosage and administration, Drugs -- Economic aspects, Escherichia coli infections -- Prevention, Medicare -- Usage, Business, Business, international, Health care industry
Published
2008

37. United States : Intermountain Healthcare Pharmacy Services Working to Help Make Medications More Affordable for Patients

Subjects
Drugs -- Economic aspects, Health care industry -- Economic aspects, Patient compliance -- Economic aspects, Pharmacy -- Economic aspects, Drugstores -- Economic aspects, Health care industry, Business, international
Abstract

'Ensuring access to and affordability of healthcare services has always been and will always be a central focus of Intermountain Healthcare.' With medication prices on the rise, people are often [...]

Published
2016

38. Inpatient versus outpatient sales

Subjects
Drugs -- Economic aspects, Outpatients -- Services, Patients -- Services, Business, Health, Health care industry, Pharmaceuticals and cosmetics industries
Published
2001

39. HCFA Mandates Medicaid Reimbursement for AIDS Wasting Drug

Subjects
Medicaid -- Economic aspects, Drugs -- Economic aspects, Wasting syndrome -- Drug therapy, Business, Health, Health care industry, National Association of People with AIDS -- Political activity, Serostim (Medication) -- Evaluation
Published
1999

40. States set cost limits for pricey prescription drugs

Author

Zweig, Dori

Subjects
Drugs -- Economic aspects, Prescriptions (Drugs) -- Economic aspects, Health care industry
Abstract

Byline: Dori Zweig In an effort to limit consumer spending on specialty drugs, several states have capped the out-of-pocket payments of patients in private health plans, http://khn.org/news/states-limiting-patient-costs-for-high-priced-drugs/?utm_content=buffer9abbc&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer Kaiser Health News [...]

Published
2015

41. Aetna, other payers lower costs of HIV drugs

Author

Zweig, Dori

Subjects
Aetna Inc., Insurance industry -- Economic aspects, Anti-HIV agents -- Economic aspects, AIDS (Disease) -- Economic aspects, Drugs -- Economic aspects, HIV -- Economic aspects, Insurance industry, Health care industry
Abstract

Byline: Dori Zweig After http://www.fiercehealthpayer.com/story/aetna-other-payers-hot-seat-allegedly-discriminating-against-hiv-patients/2014-12-23 , insurers are reducing out-of-pocket costs for these pricey medications, http://www.bloomberg.com/news/articles/2015-03-27/aetna-to-cut-co-payments-for-most-aids-drugs-after-complaint Bloomberg . Aetna announced last week that it will move the drugs into a [...]

Published
2015

42. India is the leading supplier of drugs to UN; Affordable healthcare still beyond reach of many, but India becomes top supplier of pharmaceutical products to the world

Subjects
Drugs -- Economic aspects, Health care industry -- Economic aspects, Vaccines -- Economic aspects, AIDS (Disease) -- Drug therapy -- Economic aspects, Health care industry, News, opinion and commentary, Doctors Without Borders, United Nations. Children's Fund
Abstract

Byline: Priyanka Golikeri Bangalore: Even as millions remain deprived of affordable healthcare in India, the country has emerged as the biggest supplier of healthcare products to the United Nations. In [...]

Published
2013

43. India leads in supply of drugs to UN; harsh irony | Affordable healthcare remains a distant reality inside the country

Subjects
Drugs -- Economic aspects, Health care industry -- Economic aspects, Vaccines -- Economic aspects, AIDS (Disease) -- Economic aspects, Health care industry, News, opinion and commentary, Doctors Without Borders, United Nations. Children's Fund
Abstract

Byline: Priyanka Golikeri Bangalore: Even as millions of people remain deprived of affordable healthcare in India, the country has emerged as the biggest supplier of healthcare products to the United [...]

Published
2013

44. Big pharma's greed continues to drive up healthcare spending and prices

Author

Shinkman, Ron

Subjects
Drugs -- Economic aspects, Health care industry -- Economic aspects, Medical economics -- Economic aspects, Health care industry
Abstract

Byline: Ron Shinkman There's currently a schism between healthcare prices and healthcare spending. Prices are budging only grudgingly. That's likely the confluence of the Great Recession, the Affordable Care Act [...]

Published
2015

45. Drug Sponsors Challenged to Contain Health Care Costs While Boosting Productivity, According to Tufts Center for the Study of Drug Development

Subjects
Health care costs -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Forecasts and trends -- Economic aspects, Cost control -- Economic aspects, Health care industry, Cost reduction, Market trend/market analysis, Business, Business, international, News, opinion and commentary
Abstract

Byline: BOSTON, MA, Jan 08, 2015 (Marketwired via COMTEX) -- Drug developers will implement strategies over the next year to improve clinical study performance to help control R&D costs and [...]

Published
2015

47. Benefits plans excluding more drugs as costs rise

Author

Eastwood, Brian

Subjects
Express Scripts Inc., Health maintenance organizations -- Economic aspects, Drugs -- Economic aspects, Health care industry, Advair Diskus (Medication)
Abstract

Byline: Brian Eastwood Express Scripts, CVS Health and Medicaid rank among the prescription benefit managers banning specialty drugs from health plan coverage in an effort to keep costs down, Bloomberg [...]

Published
2014

48. PATIENTS GETTING FREE MEDS TAKE THEM AS WELL AS THOSE WHO PAY PHARMACY PROGRAM MAY BE A WAY FORWARD IN HELPING DECREASE HEALTH CARE COSTS

Subjects
Medical care, Cost of -- Economic aspects, Drugs -- Economic aspects, Health care industry -- Economic aspects, Pharmacy -- Economic aspects, Health care industry, News, opinion and commentary
Abstract

CHAPEL HILL, N.C. -- The following information was released by the University of North Carolina - Chapel Hill: Patients receiving free or low-cost medications may not stick to their prescription [...]

Published
2014

49. Complementary Medicine Use Linked to Healthcare Cost Savings, Finds Frost & Sullivan

Subjects
Medical care, Cost of -- Economic aspects, Homeopathy -- Materia medica and therapeutics, Drugs -- Economic aspects, Health care industry -- Economic aspects, Therapeutics -- Economic aspects, Alternative medicine -- Economic aspects, Health care industry, Business, News, opinion and commentary
Abstract

Targeted use of complementary medicines significantly reduces risk of disease-related events, hospitalisation costs and productivity losses SYDNEY, Oct. 14, 2014 /PRNewswire/ -- Escalating healthcare costs associated with the increasing burden [...]

Published
2014

50. Will insurer cost-sharing limit consumer access to drugs?

Author

Overland, Dina

Subjects
Medical care, Cost of -- Economic aspects, Drugs -- Economic aspects, Health care industry
Abstract

Byline: Dina Overland The pharmaceutical industry is concerned that cost-sharing within most health insurance exchange plans could limit consumers' access to necessary medications, says a new report from the Breakaway [...]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results